ES2181055T3 - Formulaciones galenicas que contienen antagonistas de opiaceos. - Google Patents
Formulaciones galenicas que contienen antagonistas de opiaceos.Info
- Publication number
- ES2181055T3 ES2181055T3 ES97954355T ES97954355T ES2181055T3 ES 2181055 T3 ES2181055 T3 ES 2181055T3 ES 97954355 T ES97954355 T ES 97954355T ES 97954355 T ES97954355 T ES 97954355T ES 2181055 T3 ES2181055 T3 ES 2181055T3
- Authority
- ES
- Spain
- Prior art keywords
- optiace
- antagonists
- formulations containing
- galenic formulations
- active substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
SE DESCRIBE UNA COMPOSICION FARMACEUTICA PARA ADMINISTRACION LOCAL, QUE INCLUYE PARTICULAS QUE CONTIENEN NALOXONA, NMETILNALOXONA Y/O N-METILNALTREXONA, QUE LIBERAN LA SUSTANCIA ACTIVA SEGUN EL PH AMBIENTE. ESTO ASEGURA LA LIBERACION DE LA SUSTANCIA ACTIVA EN TODO EL TRACTO GASTROINTESTINAL. LOS EFECTOS SECUNDARIOS PROVOCADOS POR EL USO DE OPIOIDES ANALGESICOS, TALES COMO EL ESTREÑIMIENTO, QUEDAN ASI ELIMINADOS SIN QUE SE DISMINUYA EL EFECTO ANALGESICO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19651551A DE19651551C2 (de) | 1996-12-11 | 1996-12-11 | Opioidantagonisthaltige galenische Formulierung |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2181055T3 true ES2181055T3 (es) | 2003-02-16 |
Family
ID=7814396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES97954355T Expired - Lifetime ES2181055T3 (es) | 1996-12-11 | 1997-12-04 | Formulaciones galenicas que contienen antagonistas de opiaceos. |
Country Status (10)
Country | Link |
---|---|
US (1) | US6419959B1 (es) |
EP (1) | EP0938316B1 (es) |
JP (1) | JP5065548B2 (es) |
AT (1) | ATE220907T1 (es) |
CA (1) | CA2273353C (es) |
DE (2) | DE19651551C2 (es) |
DK (1) | DK0938316T3 (es) |
ES (1) | ES2181055T3 (es) |
PT (1) | PT938316E (es) |
WO (1) | WO1998025613A2 (es) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19718012C1 (de) * | 1997-04-29 | 1998-10-08 | Jenapharm Gmbh | Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe |
US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
US6559158B1 (en) | 1997-11-03 | 2003-05-06 | Ur Labs, Inc. | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
US6274591B1 (en) * | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
CA2314893C (en) | 1997-12-22 | 2005-09-13 | Euro-Celtique, S.A. | Opioid agonist/antagonist combinations |
CN1204890C (zh) | 1997-12-22 | 2005-06-08 | 欧罗赛铁克股份有限公司 | 防止阿片样物质滥用的方法 |
DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
US6451806B2 (en) | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
US6469030B2 (en) | 1999-11-29 | 2002-10-22 | Adolor Corporation | Methods for the treatment and prevention of ileus |
BR0108379A (pt) * | 2000-02-08 | 2002-11-05 | Euro Celtique Sa | Composições de liberação controlada contendo agonista e antagonista opióide, método para a preparação de uma formulação em dosagem de analgésico opióide de liberação controlada com potência analgésica aumentada e sistema de administração através da derme para um analgésico opióide |
US6716449B2 (en) | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
DE60238756D1 (de) | 2001-05-11 | 2011-02-10 | Endo Pharmaceuticals Inc | Opioid enthaltende arzneiform gegen missbrauch |
CA2778114A1 (en) * | 2001-05-11 | 2002-11-21 | Endo Pharmaceuticals, Inc. | Abuse-resistant opioid dosage form |
ATE446751T1 (de) | 2001-06-05 | 2009-11-15 | Univ Chicago | Verwendung von methylnaltrexon zur behandlung von immunsuppression |
AU2002316738B2 (en) | 2001-07-18 | 2009-01-08 | Euro-Celtique S.A. | Pharmaceutical combinations of oxycodone and naloxone |
WO2003013433A2 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique S.A. | Sequestered antagonist formulations |
HUP0401191A3 (en) | 2001-08-06 | 2006-11-28 | Euro Celtique Sa | Opioid agonist formulations with releasable and sequestered antagonist and process for their preparation |
EP2236161A1 (en) | 2001-10-18 | 2010-10-06 | Nektar Therapeutics | Polymer conjugates of opioid antagonists |
EP1492506B2 (en) * | 2002-04-05 | 2016-06-29 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
SI1551372T1 (en) | 2002-09-20 | 2018-08-31 | Alpharma Pharmaceuticals Llc | SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES |
AU2013203378B2 (en) * | 2003-04-08 | 2016-09-15 | Progenics Pharmaceuticals, Inc. | Pharmaceutical formulations containing methylnaltrexone |
DK2368554T3 (en) * | 2003-04-08 | 2015-01-26 | Progenics Pharm Inc | A pharmaceutical composition comprising methylnaltrexone |
WO2004091665A1 (en) * | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist |
JP2006522817A (ja) * | 2003-04-08 | 2006-10-05 | プロジェニックス ファーマシューティカルズ,インコーポレーテッド | 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用 |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
TWI347201B (en) | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
US20060182692A1 (en) | 2003-12-16 | 2006-08-17 | Fishburn C S | Chemically modified small molecules |
CN1925875A (zh) * | 2003-12-16 | 2007-03-07 | 尼克塔治疗亚拉巴马公司 | 化学改性的小分子 |
EP1604667A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the restless leg syndrome |
EP1604666A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
WO2006078842A1 (en) * | 2005-01-20 | 2006-07-27 | Progenics Pharmaceuticals, Inc. | Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction |
AU2006208627B8 (en) * | 2005-01-28 | 2009-08-13 | Mundipharma Pty Limited | Alcohol resistant dosage forms |
EP1695700A1 (en) | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
MX2007010833A (es) | 2005-03-07 | 2009-02-17 | Univ Chicago | Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales. |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
US20080194611A1 (en) * | 2005-06-03 | 2008-08-14 | Alverdy John C | Modulation of Cell Barrier Dysfunction |
DE102006006532B4 (de) | 2006-02-10 | 2007-11-08 | Biogenerics Pharma Gmbh | Pharmazeutische Zubereitung |
DK2526932T3 (en) | 2006-06-19 | 2017-07-17 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
US20080139654A1 (en) * | 2006-12-09 | 2008-06-12 | Eric Mott Soderling | Acetaminophen compositions having minimized side effects including reduced hepatotoxicity |
CA2865661C (en) | 2007-03-29 | 2016-05-17 | Progenics Pharmaceuticals, Inc. | Peripheral opioid receptor antagonists and uses thereof |
CN101801979A (zh) | 2007-03-29 | 2010-08-11 | 普罗热尼奇制药公司 | (r)-n-溴化甲基纳曲酮的晶体形式及其用途 |
SI2565195T1 (sl) | 2007-03-29 | 2015-09-30 | Wyeth Llc | Periferalni opioidni receptorji in antagonisti in njih uporaba |
WO2009051824A2 (en) * | 2007-10-18 | 2009-04-23 | Aiko Biotechnology | Combination analgesic employing opioid and neutral antagonist |
US8748448B2 (en) | 2007-10-18 | 2014-06-10 | Aiko Biotechnology | Combination analgesic employing opioid agonist and neutral antagonist |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
JP5358587B2 (ja) | 2008-02-06 | 2013-12-04 | プロジェニックス・ファーマシューティカルス・インコーポレイテッド | (r),(r)−2,2’−ビス−メチルナルトレキソンの製造及び用途 |
CA2719134C (en) | 2008-03-21 | 2015-06-30 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
US20110250278A1 (en) | 2008-07-01 | 2011-10-13 | University Of Chicago | Particles containing an opioid receptor antagonist and methods of use |
CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
MX347106B (es) | 2009-03-10 | 2017-04-12 | Euro-Celtique S A * | Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona. |
WO2010151741A1 (en) * | 2009-06-25 | 2010-12-29 | Elite Laboratories, Inc. | Abuse resistant oral dosage forms |
AR080491A1 (es) | 2010-03-11 | 2012-04-11 | Wyeth Llc | Formulaciones orales y sales lipofilicas de metilnaltrexona |
EA201291211A1 (ru) | 2010-05-10 | 2013-05-30 | Эро-Селтик С.А. | Фармацевтические композиции, содержащие гидроморфон и налоксон |
US9901540B2 (en) | 2010-05-10 | 2018-02-27 | Euro-Celtique S.A. | Combination of active loaded granules with additional actives |
CN103002882B (zh) | 2010-05-10 | 2016-03-02 | 欧洲凯尔特公司 | 不含活性剂之颗粒及包含其之片剂的制备 |
CA2918004C (en) | 2013-07-23 | 2018-11-20 | Euro-Celtique S.A. | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
CA2919892C (en) | 2013-08-12 | 2019-06-18 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
KR102194174B1 (ko) | 2013-11-13 | 2020-12-23 | 유로-셀티큐 에스.에이. | 통증 및 오피오이드 장 기능장애 증후군의 치료를 위한 히드로모르폰 및 날록손 |
US10105360B2 (en) | 2013-12-11 | 2018-10-23 | Develco Pharma Schweiz Ag | Method and composition for the treatment of opioid induced constipation |
WO2015086528A1 (de) | 2013-12-11 | 2015-06-18 | Develco Pharma Schweiz Ag | Naloxon-monopräparat und mehrschichttablette |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9707184B2 (en) | 2014-07-17 | 2017-07-18 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
CN107249327A (zh) | 2014-10-17 | 2017-10-13 | 萨利克斯药品公司 | 使用甲基纳曲酮减缓肿瘤进展 |
EP3209282A4 (en) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
US20160256451A1 (en) | 2015-03-06 | 2016-09-08 | Develco Pharma Schweiz Ag | Dosage of naloxone |
US20160256452A1 (en) * | 2015-03-06 | 2016-09-08 | Develco Pharma Schweiz Ag | Composition Of Opioid Receptor Antagonists For Use In Treatment Of Constipation With Highly Increased Whole Gut Transit Time |
WO2016193456A2 (en) | 2015-06-03 | 2016-12-08 | Develco Pharma Schweiz Ag | Opioid receptor antagonist for use in treating patients with severe constipation |
EP3290027A1 (en) | 2016-09-02 | 2018-03-07 | Develco Pharma Schweiz AG | Method and composition for the treatment of opioid induced constipation |
WO2020225395A1 (en) | 2019-05-07 | 2020-11-12 | Bausch Health Ireland Limited | Liquid oral dosage formulations of methylnaltrexone |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3966940A (en) | 1973-11-09 | 1976-06-29 | Bristol-Myers Company | Analgetic compositions |
US4987136A (en) * | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
WO1983003197A1 (en) * | 1982-03-16 | 1983-09-29 | Univ Rockefeller | Method for controlling gastrointestinal dysmotility |
US4774230A (en) | 1988-03-26 | 1988-09-27 | Ivax Laboratories, Inc. | Glucuronic acid derivatives of opioid antagonists |
EP0352361A1 (en) * | 1988-07-29 | 1990-01-31 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
DE4325465B4 (de) * | 1993-07-29 | 2004-03-04 | Zenz, Michael, Prof. Dr.med. | Orales pharmazeutisches Präparat für die Schmerztherapie |
DK0914097T3 (da) | 1996-03-12 | 2002-04-29 | Alza Corp | Sammensætning og doseringsform omfattende opioid antagonist |
-
1996
- 1996-12-11 DE DE19651551A patent/DE19651551C2/de not_active Expired - Fee Related
-
1997
- 1997-12-04 WO PCT/EP1997/006789 patent/WO1998025613A2/de active IP Right Grant
- 1997-12-04 DK DK97954355T patent/DK0938316T3/da active
- 1997-12-04 JP JP52618398A patent/JP5065548B2/ja not_active Expired - Fee Related
- 1997-12-04 PT PT97954355T patent/PT938316E/pt unknown
- 1997-12-04 US US09/319,818 patent/US6419959B1/en not_active Expired - Fee Related
- 1997-12-04 ES ES97954355T patent/ES2181055T3/es not_active Expired - Lifetime
- 1997-12-04 CA CA2273353A patent/CA2273353C/en not_active Expired - Fee Related
- 1997-12-04 AT AT97954355T patent/ATE220907T1/de active
- 1997-12-04 DE DE59707812T patent/DE59707812D1/de not_active Expired - Lifetime
- 1997-12-04 EP EP97954355A patent/EP0938316B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2273353A1 (en) | 1998-06-18 |
JP2001505897A (ja) | 2001-05-08 |
DE19651551C2 (de) | 2000-02-03 |
CA2273353C (en) | 2011-02-08 |
DE19651551A1 (de) | 1998-06-18 |
WO1998025613A2 (de) | 1998-06-18 |
EP0938316B1 (de) | 2002-07-24 |
PT938316E (pt) | 2002-12-31 |
DK0938316T3 (da) | 2002-10-21 |
US6419959B1 (en) | 2002-07-16 |
EP0938316A2 (de) | 1999-09-01 |
JP5065548B2 (ja) | 2012-11-07 |
WO1998025613A3 (de) | 1998-10-29 |
ATE220907T1 (de) | 2002-08-15 |
DE59707812D1 (de) | 2002-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2181055T3 (es) | Formulaciones galenicas que contienen antagonistas de opiaceos. | |
ATE260646T1 (de) | Schnell zerfallende orale dosierungsform | |
IL136285A0 (en) | Pharmaceutical compositions containing an acid-labile active component | |
IL116673A (en) | Stable oral pharmaceutical composition containing an acid labile benzimidazole | |
BR9810495A (pt) | Composição farmacêutica | |
BG66093B1 (bg) | Състави с контролирано освобождаване, съдържащи нимесулид | |
TR199801861T2 (xx) | Farmas�tik olarak yararl� bile�imler. | |
NO20004788D0 (no) | Kombinasjon for behandling av alkohol- og medikamentavhengighet inneholdende en opoid-antagonist og en NMDA reseptorkompleksmodulator | |
SE0102843L (sv) | Stabiliserad oral farmaceutisk komposition innehållande jodid och jodat och metod | |
DK1104289T3 (da) | Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister | |
ATE252377T1 (de) | Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff | |
ATE353224T1 (de) | Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz | |
TR200200683T2 (tr) | Oral kontrollü salıverme formülasyonları. | |
FR2793685B1 (fr) | Compositions pharmaceutiques, destinees a l'administration par voie orale de phloroglucinol et leur preparation | |
AR043016A2 (es) | Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene | |
GEP20043377B (en) | Pharmaceutical Complex | |
MY141008A (en) | Oral formulations of deoxypeganine and their uses | |
MY152490A (en) | New oral formulation | |
ATE429905T1 (de) | Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung |